Development of a Multimodal AI System for GIST Management
A legfontosabb adatok
- Ki végzi
- Qun Zhao
- Hol
- Kína9 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 300 fő vett részt
- Kezdés
- 2026. márc. 1.
- Befejezés
- 2026. júl. 1.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- Multimodal AI Analysis System
- A regiszteradat frissítve
- 2026. október 6.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
A regiszter feltételei, szó szerint
Mind a 10 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 years, gender not limited
- Clinical diagnosis of gastric submucosal tumor (SMT) or suspected gastrointestinal stromal tumor (GIST) based on gastroscopy or ultrasound
- Scheduled for surgical resection or endoscopic biopsy at the study center
- Standard preoperative contrast-enhanced CT scans are available (performed within 2 weeks prior to surgery)
- Patients or their legal guardians have signed the informed consent form
Ki nem vehet részt
- Received neoadjuvant therapy (e.g., Imatinib, chemotherapy, or radiotherapy) prior to surgery/biopsy
- Incomplete clinical data or lost to follow-up immediately after surgery
- Confirmed diagnosis of other primary malignancies
- Poor quality of CT images (e.g., severe motion artifacts) affecting radiomics analysis
- Insufficient tissue samples for pathological diagnosis or genetic testing
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Background: Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Accurate pre-operative diagnosis, risk stratification, and genotyping are critical for determining the appropriate surgical approach and targeted therapy (such as Imatinib). However, current methods often rely on invasive postoperative pathology and expensive genetic testing.
A teljes eredeti leírásKevesebb
Study Objective: The purpose of this study is to develop and validate a multimodal Artificial Intelligence (AI) model that integrates clinical data, CT radiomics (imaging features), and pathomics (digital pathology features) to improve the precision of GIST management.
Study Design: This is a prospective, observational study. The researchers will recruit patients with suspected gastric submucosal tumors who are scheduled for surgery or biopsy at The Fourth Hospital of Hebei Medical University.
Core Tasks: The AI model will be trained to perform three specific tasks:
Diagnosis: Distinguish GISTs from other non-GIST mesenchymal tumors (e.g., leiomyomas, schwannomas).
Risk Assessment: Stratify GISTs into risk categories (e.g., Low vs. High risk) to predict malignant potential.
Genotyping: Predict specific gene mutations (e.g., KIT or PDGFRA mutations) to guide immunotherapy or targeted therapy.
Methodology: Patient data (CT scans, pathology slides, and clinical history) will be collected and analyzed by the AI system. The AI's predictions will be compared against the "Gold Standard" results derived from postoperative pathological examination and Next-Generation Sequencing (NGS). This study is non-interventional; the AI results will not affect the standard of care received by the patients.
A vizsgált kezelések
- Multimodal AI Analysis System
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Development and Validation of a Multimodal Artificial Intelligence Model Integrating CT Radiomics, Pathomics, and Clinical Features for the Diagnosis, Risk Stratification, and Genotype Prediction of Gastrointestinal Stromal Tumors
- A regiszteradat frissítve
- 2026. október 6.